PHRMASI.BO · BSE
PHAARMASIA LTD.
₹90
+0.00% (₹0)
Prev. close
₹90
Volume
127
As of
23 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About PHAARMASIA LTD.
Phaarmasia Limited manufactures and sells oral contraceptive pills in India. It also engages in the manufacture and marketing of cosmetics and combi pack with iron tablets. Phaarmasia Limited was incorporated in 1981 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Yallapragada Naga Bhaskara Rao
Headquarters
Hyderabad
Employees
47
Website
phaarmasia.inExchange
View on BSE ↗Key stats
Market cap
₹61.44 Cr
P/E ratio (TTM)
3.5
EPS (TTM)
₹25.84
Beta (1Y · daily vs NIFTY 50)
0.35
Beta (5Y · monthly vs NIFTY 50)
2.50
Shares float
14.50 L
EPS · quarter ended Jun 2026
₹0.50
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide. Net income is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹19.90 Cr | ₹17.22 Cr | ₹27.49 Cr | ₹30.59 Cr | ₹24.37 Cr | ₹47.21 Cr | |
| EBITDA | ₹83.19 L | ₹-1.27 Cr | ₹-1.04 Cr | ₹-18.11 L | ₹-1.27 Cr | ₹21.78 Cr |
| — | — | ₹-1.26 Cr | ₹-51.82 L | ₹-1.59 Cr | ₹17.57 Cr | |
| Diluted EPS | — | — | ₹-1.84 | ₹-0.76 | ₹-2.33 | ₹25.74 |
Depreciation & amortisation, Net income, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹28.42 Cr | ₹31.45 Cr | ₹21.56 Cr | ₹30.06 Cr | |
| — | — | ₹27.38 L | ₹14.41 L | ₹1.48 L | ₹1.12 Cr | |
| Stockholders' equity | — | — | ₹10.81 Cr | ₹10.30 Cr | ₹8.74 Cr | ₹22.10 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹64.99 L | ₹10.72 L | ₹-36,000 | ₹-16.41 Cr | |
| Investing cash flow | — | — | ₹-1.22 L | ₹-12,000 | ₹-12.11 L | ₹26.15 Cr |
| — | — | ₹-16.24 L | ₹-16.24 L | ₹-14.51 L | ₹88.68 L | |
| Capital expenditure | — | — | ₹-2.58 L | ₹-3.27 L | ₹-16.80 L | — |
| End cash position | — | — | ₹69.03 L | ₹63.39 L | ₹36.42 L | ₹10.99 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| PHAARMASIA LTD. | ₹61.44 Cr | ₹90 | 3.5 | 2.78 | 79.5% | 0.05 | +93.7% | +136.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 28
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Phaarmasia standalone net profit rises 25.93% in the June 2026 quarter
Business Standard · 1 month ago